PTC Therapeutics PTCT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's deferred revenue?
- PTC Therapeutics (PTCT) reported deferred revenue of $498K in Q1 2026.
- How has PTC Therapeutics's deferred revenue changed year-over-year?
- PTC Therapeutics's deferred revenue decreased by 96.1% year-over-year, from $12.83M to $498K.
- What is the long-term trend for PTC Therapeutics's deferred revenue?
- Over 4 years (2020 to 2025), PTC Therapeutics's deferred revenue has grown at a -16.3% compound annual growth rate (CAGR), from $4.15M to $2.04M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.